Orchard Therapeutics raised a further $150 million to fund the biotech company’s work in gene therapy, building on earlier fundraisings worth more than $140 million.
Anika announced a research collaboration with the Institute of Integrative Biology at the University of Liverpool to develop an injectable mesenchymal stem cell therapy for osteoarthritis.
Following a failed Phase III vaccine for stem cell transplant recipients, San Diego-based Vical Incorporated is slashing 54 percent of its employees and focusing the company’s remaining resources on two mid-stage candidates.
Loxo Oncology struck a deal with Bayer AG to develop and commercialize two cancer therapies worth up to $1.55 billion.
Vitamin C may “tell” faulty stem cells in the bone marrow to mature and die normally, instead of multiplying to cause blood cancers. This is the finding of a study led by researchers from Perlmutter Cancer Center at NYU Langone Health, and published online August 17, 2017, in the journal Cell.
Johnson & Johnson’s Janssen Biotech opted out of its licensing deal with Los Angeles-based Capricor Therapeutics for CAP-1002 (allogeneic cardiosphere-derived cells).
